department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

IVERMECTIN · pharmadog

pharmadog
drugs
IVERMECTIN

drug

patient view →

IVERMECTIN

Marketedupdated 2mo ago

by Mountain Valley MD Holdings Inc

Approved

community read0 votes

all catalysts(2)

approval · 2

IVERMECTIN — FDA approval

IVERMECTIN — FDA approval

News(1)

Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
“We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
stat · 2mo ago

brand

IVERMECTIN

generic

IVERMECTIN

indication

Coronavirus Disease 2019 (COVID-19)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 13, 2034

~7.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (5)

Mar 13, 2034method-of-use (U-1631)US 10206939
Mar 13, 2034method-of-use (U-1631)US 9089587
Mar 13, 2034method-of-use (U-1631)US 9233117
Mar 13, 2034method-of-use (U-1631)US 9233118
Mar 13, 2034method-of-use (U-1631)US 9782425

🐶 often sniffed alongside

top 5

tagApproval6 co-mentions · 3 sources
drugMDC-STM3 co-mentions · 3 sources
tagSmall Molecule3 co-mentions · 3 sources
companyZydus Lifesciences Ltd1 co-mentions · 1 sources
companyAjanta Pharma Ltd1 co-mentions · 1 sources

Trials studying IVERMECTIN

phase2Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancerrecruitingn=34
phase3COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)completedn=1,323
phase2Rosacea and Ivermectincompletedn=30
phase3Evaluation of Effectiveness of ALBENDAZOLIVERMECTIN Coformulation vs ALBENDAZOLE for Treatment of Intestinal Wormsterminatedn=1,001
phase2A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Preventioncompletedn=400
phase1Bioequivalence Study of Ivermectin 1% Cream and Soolantra (Ivermectin) 10 mg/g Creamcompletedn=44
phase2Emodepside Phase II Trial for Treatment of Onchocerciasisactive not recruitingn=578
phase1Bioequivalence Study to Compare Two Tablets of Ivermectin Tablets (3 mg Ivermectin) Versus Two Tablets of Stromectol ® Tablets (3 mg Ivermectin), in Healthy Subjects Under Fasting Conditionscompletedn=50

more trials →